List of Excipients in Branded Drug LONHALA MAGNAIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sunovion Pharmaceuticals Inc	LONHALA MAGNAIR	glycopyrrolate	63402-201	CITRIC ACID MONOHYDRATE
Sunovion Pharmaceuticals Inc	LONHALA MAGNAIR	glycopyrrolate	63402-201	HYDROCHLORIC ACID
Sunovion Pharmaceuticals Inc	LONHALA MAGNAIR	glycopyrrolate	63402-201	SODIUM CHLORIDE
Sunovion Pharmaceuticals Inc	LONHALA MAGNAIR	glycopyrrolate	63402-201	SODIUM HYDROXIDE
Sunovion Pharmaceuticals Inc	LONHALA MAGNAIR	glycopyrrolate	63402-201	WATER

Lonhala Magnair Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Lonhala Magnair is a nebulized glycopyrrolate product for maintenance treatment of chronic obstructive pulmonary disease (COPD). Its commercial position depends on three linked assets: a low-dose sterile inhalation solution, single-use unit-dose packaging, and the Magnair eFlow vibrating-membrane nebulizer. The excipient platform is intentionally simple, but it creates opportunities in preservative-free inhalation manufacturing, sterile filling, container-closure systems, alternative nebulizer devices, and generic or follow-on products.

What is Lonhala Magnair and how is it administered?

Lonhala Magnair contains glycopyrrolate, a long-acting muscarinic antagonist, at a strength of 25 mcg per 1 mL vial. The product is administered twice daily using the Magnair nebulizer system. It is approved for long-term maintenance treatment of airflow obstruction in patients with COPD and is not indicated for acute bronchospasm relief. [1]

Attribute	Lonhala Magnair profile
Active ingredient	Glycopyrrolate
Drug class	Long-acting muscarinic antagonist
Dosage form	Sterile inhalation solution
Strength	25 mcg/1 mL
Administration	Nebulized inhalation
Dosing frequency	Twice daily
Device	Magnair nebulizer
Regulatory pathway	FDA-approved NDA
FDA application	NDA 208895
Primary market	COPD maintenance therapy
Biosimilar exposure	None; glycopyrrolate is a small molecule
Generic pathway	ANDA, subject to product and device requirements

The product is differentiated from dry-powder inhalers and metered-dose inhalers because it delivers glycopyrrolate through a portable nebulizer. This design targets patients who have difficulty generating the inspiratory flow required by some inhalers or who have problems coordinating actuation and inhalation.

What excipients are used in Lonhala Magnair?

Lonhala Magnair uses a preservative-free aqueous formulation. The FDA prescribing information identifies sodium chloride, citric acid, sodium citrate, and water for injection as inactive ingredients. [1]

Excipient	Formulation role	Commercial significance
Sodium chloride	Tonicity adjustment	Supports tolerability and osmolality control
Citric acid	Acidic pH adjustment	Helps establish formulation pH
Sodium citrate	Buffer component	Controls pH during storage and administration
Water for injection	Sterile vehicle	Required for parenteral-grade inhalation manufacture

The formulation does not rely on a complex solubilizing system, lipid carrier, surfactant package, or preservative. That reduces excipient-related safety and compatibility risks but increases the importance of sterile processing, pH control, container-closure integrity, and control of extractables and leachables.

The precise quantitative composition is not fully disclosed in the public prescribing information. Commercial development decisions therefore cannot rely solely on the inactive-ingredient list. The target product profile must also address pH, osmolality, glycopyrrolate assay, impurities, delivered dose, droplet-size distribution, nebulization time, and stability in the unit-dose vial.

Why is a simple excipient system commercially important?

A simple solution formulation can reduce development complexity. Glycopyrrolate is present at a very low concentration, so the central formulation problem is not high drug loading. It is maintaining chemical stability and consistent aerosol delivery at microgram doses.

The main commercial advantages are:

1. A limited excipient set reduces the number of raw-material suppliers and analytical methods.
2. A preservative-free product avoids concerns about chronic inhalation exposure to antimicrobial preservatives.
3. A buffered solution can provide tighter pH control than an unbuffered formulation.
4. A sterile aqueous product is compatible with single-use unit-dose packaging.
5. A solution eliminates the need to disperse micronized drug particles, as required for many dry-powder inhalers.

The same design creates constraints. The product must be manufactured under sterile conditions, and a generic sponsor cannot treat the excipients as an ordinary oral-liquid formulation. Inhalation products require tight control over the delivered dose and aerodynamic performance. The device, vial, solution viscosity, fill volume, and nebulization conditions jointly determine patient exposure.

What formulation properties matter most for Lonhala Magnair competitors?

A competing product must match or closely approximate the critical performance attributes of the reference product. The most important properties are set out below.

pH and buffer capacity

Citric acid and sodium citrate provide an acidic buffered environment. The pH must balance glycopyrrolate stability, patient tolerability, and compatibility with the nebulizer pathway. Excessive buffer capacity can increase irritation risk or complicate equivalence. Insufficient buffer capacity can allow pH drift during storage.

A follow-on sponsor should evaluate:

• Initial pH and pH drift
• Buffer capacity
• Glycopyrrolate degradation under heat and light
• Interaction with the vial and nebulizer fluid path
• Aerosol performance after storage

Osmolality and sodium chloride concentration

Sodium chloride supports tonicity, but the target osmolality must be evaluated alongside the acidic buffer system. Hypertonic or hypotonic solutions may affect tolerability, cough, throat irritation, and aerosol delivery.

The commercial opportunity is strongest for suppliers that can provide highly consistent inhalation-grade sodium chloride and validated impurity profiles at sterile-manufacturing scale.

Preservative-free sterile presentation

Lonhala Magnair uses single-dose vials, allowing the formulation to avoid multidose-container preservatives. This approach shifts the control strategy toward:

• Sterile filtration or aseptic processing
• Low-bioburden raw materials
• Container-closure integrity
• Vial weld or seal performance
• Hold-time control
• Sterility and particulate testing

For excipient manufacturers, the opportunity is not limited to sodium chloride or citrate. It includes sterile, low-endotoxin, inhalation-suitable grades, ready-to-use excipient solutions, and quality packages supporting FDA submissions.

Aerosol performance

The final product is a combination product. The solution must produce an appropriate aerosol through the Magnair device. Relevant attributes include:

• Delivered dose
• Fine-particle dose
• Mass median aerodynamic diameter
• Geometric standard deviation
• Residual volume
• Nebulization time
• Dose uniformity across the treatment session

A formulation that is chemically equivalent but performs differently in the device may not provide a commercially viable substitute.

What commercial opportunities exist for excipient suppliers?

Sterile-grade sodium chloride and citrate systems

The largest direct opportunity is supply of high-purity, sterile or sterilizable sodium chloride, citric acid, and sodium citrate. Suppliers can differentiate through:

• Inhalation-specific quality documentation
• Low heavy-metal and elemental-impurity profiles
• Low endotoxin levels
• Particle-control programs
• Stable global supply
• Regulatory support for drug-master-file or customer submissions

The value proposition is stronger when the supplier provides a qualified excipient system rather than commodity materials alone.

Ready-to-use buffered vehicles

A supplier could offer a prequalified aqueous citrate buffer containing sodium chloride, with validated pH, osmolality, microbial limits, and filtration performance. Such a platform could reduce formulation development time for sterile nebulized products containing glycopyrrolate or other low-dose bronchodilators.

The commercial limitation is that a reference-product formulation may be protected by process, composition, or device-related intellectual property. A supplier must avoid assuming that a chemically simple formulation is unprotected.

Sterile filling and unit-dose packaging

The product creates demand for 1 mL unit-dose vial manufacturing, including:

• Blow-fill-seal or molded vial systems
• Low-volume sterile filling
• High-integrity seals
• Light-protective packaging where needed
• Child-resistant secondary packaging
• Barcoded dose packs
• Automated inspection for particulates and fill-volume variation

Packaging suppliers can compete on extractables and leachables data, compatibility with acidic citrate solutions, and container-closure integrity after shipping.

Alternative nebulizer platforms

The Magnair system is a central part of the product’s differentiation. Commercial opportunities may exist for alternative vibrating-mesh nebulizers that deliver equivalent or improved performance with a glycopyrrolate solution.

Potential differentiators include:

• Shorter treatment time
• Smaller and lighter hardware
• Rechargeable operation
• Lower residual volume
• Easier cleaning
• Dose tracking
• Remote adherence monitoring
• Lower manufacturing cost

A competing device may require a new drug-device combination strategy rather than a simple device substitution.

What FDA regulatory issues affect generic Lonhala Magnair development?

A generic sponsor would generally pursue an ANDA for glycopyrrolate inhalation solution. The principal regulatory challenge is demonstrating pharmaceutical equivalence and bioequivalence for a product administered through a specialized nebulizer.

The reference product combines:

• Drug formulation
• Unit-dose container
• Nebulizer hardware
• Patient interface
• Operating instructions
• Delivered-aerosol characteristics

The FDA may scrutinize comparative in vitro performance, including emitted dose, droplet-size distribution, delivered dose uniformity, residual volume, and nebulization time. Device differences can materially affect exposure even when the formulation is chemically similar.

FDA guidance for orally inhaled and nasal drug products provides the principal framework for evaluating product performance and equivalence. [2] A generic sponsor also must address labeling, device performance, manufacturing controls, and human-factors considerations where the device differs from the reference system.

What patent and exclusivity issues affect Lonhala Magnair?

Lonhala Magnair is a small-molecule product, so biosimilar competition is not relevant. Competition would arise through an ANDA, an authorized generic, a reformulated glycopyrrolate product, or a competing long-acting bronchodilator.

The relevant legal categories are:

Protection category	Relevance to Lonhala Magnair
Active-ingredient patent	Limited if glycopyrrolate itself is long off patent
Formulation patent	May cover concentration, pH, buffer, stability, or excipient ratios
Method-of-use patent	May cover COPD treatment or dosing schedules
Device patent	May cover the Magnair nebulizer or vibrating-mesh architecture
Combination-product patent	May cover the formulation used with the device
Manufacturing patent	May cover sterile filling, vial preparation, or nebulization processes
Regulatory exclusivity	Must be checked against FDA application and approval records
Orange Book listing	Must be reviewed for patents submitted for NDA 208895

The FDA Orange Book is the controlling public source for listed patents, expiration dates, pediatric exclusivity, and other listed protection associated with an approved drug application. [3] A definitive Paragraph IV assessment requires review of the current Orange Book entry and the corresponding patent documents.

A generic entrant faces two separate risk layers. The first is the drug-product layer, including formulation and method-of-use patents. The second is the device layer, including patents covering the nebulizer and the interface between the device and the unit-dose vial. A formulation-only design may not eliminate device-related litigation risk.

When does Lonhala Magnair lose exclusivity and when can generics launch?

FDA approval occurred in December 2017. [1] The standard five-year new chemical entity exclusivity period for an eligible small-molecule product would have ended in December 2022, subject to the specific regulatory classification and any applicable extensions. Product-specific patent expiration dates cannot be stated accurately without the current Orange Book listing and certified patent records.

Generic entry timing depends on:

• The earliest ANDA filing date
• Paragraph IV certifications
• The patent owner’s infringement action
• The 30-month stay under the Hatch-Waxman framework
• Any settlement agreement
• Pediatric exclusivity
• Patent-term extension
• Device-related regulatory requirements
• Commercial readiness of an equivalent nebulizer

A Paragraph IV challenge could create earlier entry than the latest listed patent expiration if the challenger obtains a favorable court judgment, reaches a license settlement, or succeeds in designing around the asserted claims.

Which companies compete with Lonhala Magnair?

Lonhala Magnair competes in the long-acting bronchodilator market rather than only against nebulized glycopyrrolate products. The relevant products include:

Product class	Examples	Competitive issue
Nebulized LAMA	Lonhala Magnair	Portable nebulizer and twice-daily use
Nebulized LABA	Arformoterol, formoterol products	Different mechanism and dosing
Dry-powder LAMA	Tiotropium products	Device-dependent inspiratory flow
Soft-mist LAMA	Tiotropium Respimat	Coordination and device training
LAMA/LABA combinations	Umeclidinium/vilanterol, tiotropium/olodaterol	Once-daily combination convenience
Generic nebulized bronchodilators	Multiple manufacturers	Lower price and broader channel access

Lonhala Magnair’s principal commercial advantages are delivery through a nebulizer and the absence of a required high inspiratory maneuver. Its disadvantages include device burden, cleaning requirements, twice-daily administration, and potentially higher product-plus-device cost.

What licensing and partnering opportunities exist?

The most credible partnering opportunities are concentrated in four areas.

Inhalation excipients

Excipient suppliers can license inhalation-grade formulations, analytical methods, or sterile vehicle platforms to generic and specialty-pharmaceutical companies.

Nebulizer technology

Device companies can pursue licensing or co-development agreements involving vibrating-mesh systems, disposable fluid paths, adherence monitoring, and connected-health functions.

Regional commercialization

A partner with established respiratory sales infrastructure may support geographic expansion, particularly in markets where nebulizer use is common and inhaler technique is a recognized barrier.

Reformulation and lifecycle management

Potential lifecycle products include:

• Once-daily glycopyrrolate nebulization
• Glycopyrrolate combination nebulization
• Smaller-volume unit doses
• Faster treatment times
• Improved portability
• Co-packaged maintenance and rescue products
• Digitally monitored nebulizer systems

Each program would require separate clinical, device, and regulatory analysis. A new concentration or dosing frequency would likely require more than an excipient change.

How strong is the Lonhala Magnair patent estate?

The commercial strength of the estate depends less on glycopyrrolate composition-of-matter rights than on formulation, device, combination-product, and manufacturing claims. The strongest potential barriers would be claims that cover the integrated product rather than a narrow excipient ratio.

A patent estate is more durable when it includes:

• Multiple claim types
• Device and formulation coverage
• Validated clinical use claims
• Manufacturing-process claims
• International coverage
• Claims that are difficult to design around without reducing aerosol performance

The practical vulnerability is that sodium chloride, citrate buffers, sterile water, and unit-dose packaging are individually common. Protection must therefore arise from the specific combination, operating parameters, device integration, or manufacturing process.

Key Takeaways

• Lonhala Magnair is a preservative-free, sterile glycopyrrolate inhalation solution delivered through the Magnair nebulizer.
• Its principal excipients are sodium chloride, citric acid, sodium citrate, and water for injection.
• The main excipient opportunities involve sterile-grade materials, prequalified citrate vehicles, unit-dose vial systems, and inhalation-specific quality packages.
• Generic development requires evaluation of both formulation equivalence and nebulizer performance.
• Biosimilar competition does not apply because glycopyrrolate is a small molecule.
• Patent risk may arise from formulation, method-of-use, device, combination-product, and manufacturing claims.
• The strongest lifecycle opportunities involve faster nebulization, connected devices, combination products, and improved unit-dose packaging.
• FDA Orange Book records and patent prosecution files are required for a definitive expiration and Paragraph IV analysis.

FAQs

Can Lonhala Magnair be reformulated without sodium chloride?

A reformulation without sodium chloride could be technically feasible, but it would require reassessment of osmolality, tolerability, stability, delivered dose, and nebulizer performance. It would not automatically qualify as equivalent to the reference product.

Are citrate buffers common in nebulized COPD products?

Citrate buffers are used in some aqueous inhalation formulations, but their acceptability depends on pH, concentration, aerosol tolerability, stability, and compatibility with the specific drug and device.

Is Lonhala Magnair a combination product?

Yes. The commercial product is a drug-device combination comprising glycopyrrolate inhalation solution and the Magnair nebulizer system. The regulatory and intellectual-property analysis must address both components.

Can a generic company use a different nebulizer?

A different nebulizer may be possible, but the sponsor must demonstrate that the complete product provides comparable performance and satisfies FDA requirements for the proposed drug-device combination.

What is the highest-value excipient opportunity linked to Lonhala Magnair?

The highest-value opportunity is a validated sterile, preservative-free aqueous vehicle and filling platform that supports low-dose inhalation products, rather than the sale of commodity sodium chloride or citrate alone.

References

1. U.S. Food and Drug Administration. (2017). Lonhala Magnair (glycopyrrolate) inhalation solution: Prescribing information. Sunovion Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally inhaled and intranasal products. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.